TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0

CUSIP: 89422GAA5

Q3 2024 13F Holders as of 30 Sep 2024

Type / Class
Debt / NOTE 2.250% 3/0
Market price (% of par)
86.4%
Total 13F principal
$257,683,037
Principal change
+$4,792,295
Total reported market value
$224,077,029
Number of holders
25
Value change
+$11,645,577
Number of buys
12
Number of sells
11

Quarterly Holders Quick Answers

What is CUSIP 89422GAA5?
CUSIP 89422GAA5 identifies 89422GAA5 - TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q3 2024

As of 30 Sep 2024, TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by 25 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $257,683,037 in principal (par value) of the bond. The largest 10 bondholders included WOLVERINE ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., OAKTREE CAPITAL MANAGEMENT LP, Linden Advisors LP, Graham Capital Management, L.P., SILVERBACK ASSET MANAGEMENT LLC, CAPSTONE INVESTMENT ADVISORS, LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, AQR Arbitrage LLC, and Point72 Asset Management, L.P.. This page lists 25 institutional bondholders reporting positions for the Q3 2024 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.